DSAQU
Direct Selling Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Plano, Texas. Direct Selling Acquisition Corp. is a subsidiary of DSAC Partners LLC.
DSAQU (DSAQU) - Net Assets
Latest net assets as of September 2024: $8.99 Million USD
Based on the latest financial reports, DSAQU (DSAQU) has net assets worth $8.99 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($31.88 Million) and total liabilities ($22.89 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.99 Million |
| % of Total Assets | 28.2% |
| Annual Growth Rate | -55.14% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 43.11 |
DSAQU - Net Assets Trend (2021–2023)
This chart illustrates how DSAQU's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DSAQU (2021–2023)
The table below shows the annual net assets of DSAQU from 2021 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $43.64 Million | -80.87% |
| 2022-12-31 | $228.20 Million | +5.35% |
| 2021-12-31 | $216.63 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to DSAQU's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28876600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $61.91 Million | 141.85% |
| Total Equity | $43.64 Million | 100.00% |
DSAQU Competitors by Market Cap
The table below lists competitors of DSAQU ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kopran Limited
NSE:KOPRAN
|
$31.83 Million |
|
Plus Therapeutics Inc
NASDAQ:PSTV
|
$31.83 Million |
|
Panca Budi Idaman Tbk PT
JK:PBID
|
$31.84 Million |
|
M.R.M. SA
PA:MRM
|
$31.86 Million |
|
Taeyang Metal Industrial Co Ltd
KO:004105
|
$31.81 Million |
|
Concraft Holding Co Ltd
TW:4943
|
$31.81 Million |
|
Direct Selling Acquisition Corp
OTCQX:DSAQ
|
$31.80 Million |
|
Solid Year Co., Ltd.
TWO:6737
|
$31.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DSAQU's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 228,204,725 to 43,644,919, a change of -184,559,806 (-80.9%).
- Net loss of 269,906 reduced equity.
- Other factors decreased equity by 184,289,900.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-269.91K | -0.62% |
| Other Changes | $-184.29 Million | -422.25% |
| Total Change | $- | -80.87% |
Book Value vs Market Value Analysis
This analysis compares DSAQU's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.04x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.55x to 3.04x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $7.53 | $11.69 | x |
| 2022-12-31 | $7.94 | $11.69 | x |
| 2023-12-31 | $3.85 | $11.69 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DSAQU utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.62%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.45x
- Recent ROE (-0.62%) is below the historical average (2.23%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 5.07% | 0.00% | 0.00x | 1.05x | $-11.24 Million |
| 2023 | -0.62% | 0.00% | 0.00x | 1.45x | $-4.63 Million |
Industry Comparison
This section compares DSAQU's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DSAQU (DSAQU) | $8.99 Million | 5.07% | 2.55x | $31.82 Million |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |